ASML Netherlands BV, a subsidiary of ASML Holding NV, is a company headquartered in Veldhoven, the Netherlands. The firm manufactures and supplies chip-making equipment.\nThe company says this about itself: ASML is one of the world's leading manufacturers of chip-making equipment. Our vision is to enable affordable microelectronics that improve the quality of life. To achieve this, our mission is to invent, develop, manufacture and service advanced technology for high-tech lithography, metrology and software solutions for the semiconductor industry. ASML's guiding principle is continuing Moore's Law towards ever smaller, cheaper, more powerful and energy-efficient semiconductors. This results in increasingly powerful and capable electronics that enable the world to progress within a multitude of fields, including healthcare, technology, communications, energy, mobility, and entertainment. ASML is a multinational company with offices in 60 cities in 16 countries, headquartered in Veldhoven, the Netherlands. We employ more than 19,000 people on payroll and flexible contracts (expressed in full time equivalents). ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML.

Manufactures healthcare equipment

BioCurity Pharmaceuticals is a biopharmaceutical company with a mission to transform a cancer patient’s recovery, by addressing a global unmet need for an effective treatment to mitigate radiation therapy toxicity. It is on track to fundamentally change the course of radiation therapy for cancer patients, worldwide. Approximately 6 million of the 18 million people who will be diagnosed with cancer every year, will receive radiation treatment. The lack of an effective treatment for the adverse side effects associated with radiation therapy represents a substantial market opportunity, but most importantly, a chance to help better the quality of life for cancer survivors around the world. BioCurity’s patented technologies and drugs in their pipeline have the potential to significantly reduce radiation toxicity, not just for newly diagnosed patients, but also for the millions of patients who must receive radiation as a part of their ongoing treatment for cancer.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Manteia Data Technology Co., Ltd. is a Chinese company located in Xiamen. The firm provides data services. It was founded in 2017.

Sck Cen is a nuclear research center that consults in irradiation services, radioactive waste, medical and nuclear applications.

Eukarion, Inc. engages in the provision of medical research. It develops small molecule drugs for the treatment of degenerative and age-related disorders. The company was founded on January 25, 1991 and is headquartered in Arlington, MA.

Del Mar Pharmaceuticals (BC) Ltd., part of Kintara Therapeutics, Inc., is a company headquartered in Vancouver, BC, Canada, that provides drug development services. It was founded by William James Garner, Dennis M. Brown and Jeffrey A. Bacha. Jeffrey A. Bacha is the current CEO, occupying that position since 2010. Kintara Therapeutics, Inc. acquired Del Mar Pharmaceuticals (BC) Ltd. on January 25, 2013 for $0.65 million.

Bioincept LLC provides pre-implantation factor technologies as they relate to animal and human diagnostic and therapeutic health products. The company was founded by Dr. Jacqueline H. Barnea and Dr. Eytan R. Barnea in 2001 and is headquartered in Cherry Hill, NJ.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

Shiseido Co., Ltd. engages in the production and sale of cosmetics for men and women. It operates through the following segments: Japan, China, Asia Pacific, Americas, Europe, Travel Retail, Professional, and Others. The Japan, China, Asia Pacific, Americas, and Europe segments sell cosmetics, fragrance, and personal care products with core brands such as Shiseido, clé de peau BEAUTÉ, ELIXIR, MAQUILLAGE, AUPRES, urara, TSUBAKI, Za, and narciso rodriguez in each corresponding region. The Travel Retail segment retails Shiseido, clé de peau BEAUTÉ, bareMinerals, and NARS brands in airport duty-free shops excluding Japan. The Professional segment manages the sale of beauty products in Japan, China, and Asia. The Others segment includes headquarter functions, production, frontier science, and restaurant businesses. The company was founded by Arinobu Fukuhara on September 17, 1872 and is headquartered in Tokyo, Japan.

Medicis Pharmaceutical Corp. develops and markets pharmaceutical products for dermatological usages. It offers a broad range of products addressing various conditions or aesthetic improvements, including facial wrinkles, glabellar lines, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis and cosmesis. The company was founded on July 28, 1988 and is headquartered in Phoenix, AZ.

Manufactures electric distribution equipments

Shanghai Enrou Technology Co., Ltd., established on 2018-09-07, Business scope includes general items:Biological Technology(human stem cells,Except genetic diagnosis and treatment),Internet technology,Information Technology,Technical services in the field of computer software and hardware technology,technology development,technical consulting,technology transfer,business inquiries,Business Management Consulting,marketing planning,design,make,acting,Publish various advertisements,Etiquette service,account Serive,Exhibition display service,cleaning supplies,Disinfectant,disinfection products,Daily necessities,Office Supplies,handcrafted gift(cultural relics,Except for ivory and its products),electronic product,Computer hardware and software,cosmetic,Wholesale of Household Goods,retail.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Neoway Medical specializes in medical CT imaging technology. The main research and development products are complete CBCT system machines with specialized features and associated clinical software for various clinical applications. It is a medical device manufacturer integrating research, production, and sales.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.